The article deals with the question of the arterial hypertension grade influence on the levels of pro-inflammatory interleukin-6 and adropin in hypertensive patients. Considering the relationship between hypertension and obesity and diabetes mellitus type 2, it was important to determine the levels of inflammatory markers in patients with isolated hypertension and in patients with concomitant hypertension, obesity and diabetes, depending on the degree of blood pressure. The purpose of the work was to reveal an influence of the grade of arterial hypertension on inflammation indicators depending on the presence of concomitant pathologists. Material and methods. The study involved 127 patients with hypertension of stage II, 1-2nd degree, 42% men, the average age was 61.9 ± 6.1 years. Patients were divided into groups depending on the degree of hypertension: the first consisted of 68 patients with grade 1 arterial hypertension; the second, 59 patients with grade II hypertension, each group being divided into 3 subgroups: the 1st – with isolated course of hypertension, the 2nd – combination of hypertension with obesity, and the 3rd – polymorbid hypertensive patients with obesity and type 2 diabetes. Results and discussion. The study results showed that there is a general pattern for all groups in the form of elevated levels of pro-inflammatory interleukin-6 in patients with hypertension compared to control. At the same time, the difference when comparing control and isolated course of hypertension of I grade was unreliable (p>0.05). In the group of patients with isolated arterial hypertension, the level of adropin in patients with II grade of hypertension was significantly lower than the control group, but was not significant in case of comparison I grade with control group (p>0.05). In patients with both grades I and II hypertension when combined with diabetes mellitus and obesity, difference of adropin levels achieved the values of reliability compared to control group (p<0.01). There were no statistically significant differences in the levels of interleukin-6 and adropin between grade I and II of arterial hypertension, except for the group of patients with isolated hypertension, where this difference turned out to be significant (p <0.05). Conclusions. The degree of increase in hypertension affects the concentrations of adropin and interleukin-6, and this effect is more pronounced in an isolated course of hypertension, while in patients with arterial hypertension in combination with diabetes and obesity, this effect is not so significant. This difference may be determined by the additional potentiation effect of obesity and diabetes on inflammatory markers.

Keywords: inflammation, arterial hypertension, obesity, diabetes mellitus, adropin

Full text: PDF (Eng) 212K

1. Bolayır HA, Kıvrak T, Gunes H, Bolayır A, Karaca I. Adropin and circadian variation of blood pressure. Kardiol Pol. 2018; 76(4): 776-82. https://www.ncbi.nlm.nih.gov/pubmed/29313563. https://doi.org/10.5603/KP.2018.0006
2. Castro AM, Macedo-de la Concha LE, Pantoja-Meléndez CA. Low-grade inflammation and its relation to obesity and chronic degenerative diseases. Revista Médica del Hospital General de México. 2017; 80(2): 101-5. https://doi.org/10.1016/j.hgmx.2016.06.011
3. De Miguel C, Rudemiller NP, Abais JM, Mattson DL. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep. 2015; 17(1): 507. https://www.ncbi.nlm.nih.gov/pubmed/25432899. https://www.ncbi.nlm.nih.gov/pmc/articles/4418473. https://doi.org/10.1007/s11906-014-0507-z
4. Demircelik B, Cakmak M, Nazli Y, Gurel OM, Akkaya N, Cetin M, et al. Adropin: A new marker for predicting late saphenous vein graft disease after coronary artery bypass grafting. Clin Invest Med. 2014; 37 (5): E338-44. https://www.ncbi.nlm.nih.gov/pubmed/25282140. https://doi.org/10.25011/cim.v37i5.22014
5. Dimova R, Tankova T. The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis. Biomed Res Int. 2015; 2015: 1–7. https://doi.org/10.1155/2015/823481
6. Druzhylov MA, Druzhylova OYu, Beteleva YuE, Kuznetsova TYu. Ozhyrenye kak faktor serdechno-sosudystoho ryska: aktsent na kachestvo y funktsyonalnuiu aktyvnost zhyrovoi tkany. Rossyiskyi kardyolohycheskyi zhurnal. 2015; 4 (120): 111-7. [Russian] https://doi.org/10.15829/1560-4071-2015-4-111-117
7. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017; 13(4): 851–63. https://www.ncbi.nlm.nih.gov/pubmed/28721154. https://www.ncbi.nlm.nih.gov/pmc/articles/5507106. https://doi.org/10.5114/aoms.2016.58928
8. Frejdin M.B. Molekuljarno-geneticheskie issledovanija komorbidnosti. Bjulleten' sibirskoj mediciny. 2015; 14(6): 94–6. [Russian]
9. Gulen B, Eken C, Kucukdagli OT, Serinken M, Kocyigit A, Kılıc E, Uyarel H. Adropin levels and target organ damage secondary to high blood pressure in the ED. Am J Emerg Med. 2016; 34(11): 2061–4. https://www.ncbi.nlm.nih.gov/pubmed/27592461. https://doi.org/10.1016/j.ajem.2016.04.014
10. Helmersson-Karlqvist J. 24-Hour ambulatory blood pressure associates inversely with prostaglandin F (2α), interleukin-6 and F(2)-isoprostane formation in a Swedish population of older men. Int J Clin Exp Med. 2012; 5(2): 145-53. https://www.ncbi.nlm.nih.gov/pubmed/22567175. https://www.ncbi.nlm.nih.gov/pmc/articles/3342711
11. Kong Q, Xia M, Liang R, Li L, Cu X, Sun Z, Hu J. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med J. 2014; 55(7): 383–7. https://www.ncbi.nlm.nih.gov/pubmed/25091888. https://www.ncbi.nlm.nih.gov/pmc/articles/4291965. https://doi.org/10.11622/smedj.2014091
12. Kumar GK, Zhong J, Gao S, Rossi J, McGuinness OP, Halmen HH, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity. 2012; 20(7): 1394–402. https://www.ncbi.nlm.nih.gov/pubmed/22318315. https://www.ncbi.nlm.nih.gov/pmc/articles/3905465. https://doi.org/10.1038/oby.2012.31
13. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010; 38(2 Suppl): 26-34. https://www.ncbi.nlm.nih.gov/pubmed/20083910. https://doi.org/10.1097/CCM.0b013e3181c98d21
14. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010; 122(11 Suppl): S185–92. https://www.ncbi.nlm.nih.gov/pubmed/20837912. https://doi.org/10.1161/CIRCULATIONAHA.109.931782
15. Quynh N. Dinh, Grant R. Drummond, Christopher G. Sobey, Sophocles Chrissobolis. Roles of Inflammation, Oxidative Stress, and Vascular Dysfunction in Hypertension. BioMed Research International. 2014; 2014 (Article ID 406960): 11. https://www.ncbi.nlm.nih.gov/pubmed/25136585. https://www.ncbi.nlm.nih.gov/pmc/articles/4124649. https://doi.org/10.1155/2014/406960
16. Yan B, Shi X, Zhang H, Pan L, Ma Z, Liu S, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS ONE. 2014; 9(4): e94235. https://www.ncbi.nlm.nih.gov/pubmed/24709991. https://www.ncbi.nlm.nih.gov/pmc/articles/3978033. https://doi.org/10.1371/journal.pone.0094235
17. Yu H, Zhao P, Wu M, Liu J, Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept. 2014; 190–191: 46–9. https://www.ncbi.nlm.nih.gov/pubmed/24731968. https://doi.org/10.1016/j.regpep.2014.04.001